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Abstract 
   The current study was undertaken in Sana'a city, Yemen, which has one of the highest rates of 
Tuberculosis (TB) in the Region. We retrospectively determined the prevalence of true RIF's mono-
resistance, using the gold standard of molecular assays comparing with culture based phenotypic drug 
susceptibility testing (DST), and determine the associated risk factors of contracting RF gene among 
Yemeni TB patients. Patient's data were collected in a predesigned questionnaire which included 
demographic information and the relevant risk factors associated with RIF. All sputum specimens received 
were routinely cultured, and, underwent phenotypic drug susceptibility testing. DNA sequences specific for 
MTB and RIF were detected by automated molecular test. The total end treatment rate was 5.94% of the 
total cases (11/185).   MTB gene was positive for all cases which indicate more sensitive than sputum 
examination; 3.2% of total patients show RIF's genes positive. Higher rate of RIF with male (5.4%), and 
low in female patients (1.8%).  There was higher rate of RIF with age group 36-45 years (8.7%) and >15 
years (7.1%). There was significant rate of RIF gene with after food drug taken (RIF=13.3%, with 
OR=6.4), and with DOTs program (RIF=10%, with OR=6.4). In addition, there was significant rate of RIF 
gene with one dose regimen (11.8%, OR=5.5). In conclusion, this study reveal the presence of RIF-
M.tuberculosis in Sana’a, Yemen and most of them were observed among patients who default treatment. 
This is considered as a threat to TB control programme and it is recommended that strategies should be put 
in place in order to ensure patients’ compliance and monitoring of patients’ response to TB treatment. 
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INTRODUCTION 
Globally in 2015, an estimated 480 000 people developed multidrug-resistant TB (MDR-TB). TB 
incidence has fallen by an average of 1.5% per year since 2000. This needs to accelerate to a 4–5% annual 
decline to reach the 2020 milestones of the "End TB Strategy". An estimated 49 million lives were saved 
through TB diagnosis and treatment between 2000 and 2015. Ending the TB epidemic by 2030 is among the 
health targets of the newly adopted Sustainable Development Goals
1
. 
When TB is detected and effectively treated, the disease is largely curable. However, in 2013, an 
estimated 9.0 million people developed TB and 1.5 million died from the disease, 360 000 of whom were 
Human Immunodeficiency Virus (HIV) positive
2
.  
In Yemen, TB is considered one of the major infectious diseases recorded in the national disease list. 
A rapidly increasing population, poor quality health services, very low annual income of individuals and 
the whole country’s poor economic status plus the Saudi-UAE's aggression is the most important factors 
responsible for the high incidence of TB in the country
3, 4
.  
Drug-resistant Mycobacterium tuberculosis, including multidrug-resistant Mycobacterium 
tuberculosis (MDR- Mycobacterium tuberculosis, defined as resistance to at least isoniazid and rifampicin, 
the two most important first-line anti-TB drugs) and extensively drug resistant TB (XDR- Mycobacterium 
tuberculosis, defined as MDR- Mycobacterium tuberculosis, plus resistance to any fluoroquinolones, such 
as ofloxacin or moxifloxacin, and to at least one of three injectable second-line drugs, amikacin, 
capreomycin, or kanamycin) has emerged as a serious threat to global health
5
. 
Rifampicin is one of the most important anti-tuberculosis (anti-TB) antibiotics; it exerts its 
bactericidal activity by inhibiting the early steps of gene transcription by binding to the ß -subunit of RNA 
polymerase (rpo ß) encoded by the rpo ß gene
6
. The control of TB has been impeded by the emergence of 
drug-resistant Mycobacterium tuberculosis strains
7
. The problem of TB has been compounded by the 
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emergence of multi-drug resistance Mycobacterium tuberculosis and Human Immunodeficiency Virus 
(HIV). The development of resistance to rifampicin is due to mutations in a well-defined 81 base pair (bp) 
(27 codons) central region of the gene that encodes the Î²-subunit of RNA polymerase (rpo ß). More than 
96% of the rifampicin-resistant strains contain a mutation in this 81 bp region of rpo ß, thus facilitating a 
straight forward approach to detecting rifampicin resistance and/or MDR rapidly
8
. Despite low sensitivity 
in detection of Mycobacterium tuberculosis, acid-fast sputum smear remains the main diagnostic method in 
most countries, especially in resource-limited settings. In HIV infected patients with pulmonary TB, 24–
61% have acid-fast negative sputum smear. In 2011, WHO advice the wide use of Xpert Mycobacterium 
tuberculosis /Rifampicin assay, a fully automated diagnostic molecular test using real-time polymerase 
chain reaction (PCR) technology to simultaneously detect Mycobacterium. Tuberculosis and rifampicin 
resistance mutations in the (rpo B) gene
9
. Xpert Mycobacterium tuberculosis /Rifampicin is an automated 
polymerase chain reaction (PCR) test (molecular test) utilizing the GeneXpert
®
 platform
9,10
.  Xpert
®
 
MTB/RIF is a single test that can detect both Mycobacterium tuberculosis complex and rifampicin 
resistance within two hours after starting the test, with minimal hands-on technical time. The Xpert 
MTB/RIF limit of detection, “the lowest number of colony forming units per sample that can be 
reproducibly distinguished from negative samples with 95% confidence”11, is five genome copies of 
purified  DNA per reaction or 131 colony forming units per mL in Mycobacterium tuberculosis spiked 
sputum
10
. In comparison, identification of TB bacilli by microscopic examination requires at least 10,000 
bacilli per ml of sputum
12
. Xpert MTB/RIF detects both live and dead bacteria
13
.  
The first nationwide prevalence survey on resistance to the four major anti-tuberculosis drugs in 
Yemen showed a relatively low prevalence of drug-resistant cases, but a high prevalence of multidrug 
resistance among new cases
14
. The current study aim's was to determine prevalence of true RIF's mono-
resistance, using the gold standard of molecular assays comparing with culture based phenotypic drug 
susceptibility testing (DST), and determine the associated risk factors of contracting RF gene among 
Yemeni TB patients. 
 
MATERIALS AND METHODS 
This cross-sectional laboratory study conducted among pulmonary patients attending the National 
Tuberculosis Control Programme (NTCP) in Sana'a city, Yemen. During the period from March, 2017 until 
December, 2017.  Data was taken from each subject and collected in a predesigned questionnaire which 
included demographic information, detailed clinical history and risk factors associated with Rifampicin-
mono-resistant Mycobacterium tuberculosis. The patients were categorized to; (i) patients that had 
previously received treatment in the same or another clinic but default after some time (ii) patients whose 
treatment history could not be assessed, (iii) patients that visit the clinic for the first time and (iv) patients 
who had relapse after completion of normal treatment plan. Three  sputum samples were collected from 
each patient, then one tested for acid fast bacilli, the second  mixed with 2 ml of buffer for genetic test 
(Genexpert), and the third specimen for culture based phenotypic drug susceptibility testing (DST) . The 
GeneXpert System equipped with GX2.1 software/computer/printer/barcode wand-reader and operator 
manual (Cepheid Inc, Sunnyvale, and USA). The GenXpert MTB/RIF is an automated molecular test 
which detects DNA sequences specific for MTB and RIF's resistance by polymerase chain reaction with 
fully integrated sample processing in patients suspected of drug sensitive or multidrug resistant pulmonary 
tuberculosis. Also, the prevalence of true RIF mono-resistance, using the gold standard of molecular assays 
(The GenXpert MTB/RIF) was comparing with culture based phenotypic drug susceptibility testing (DST). 
In addition, we determine the associated risk factors of contracting RF gene among Yemeni TB patients as 
described in result tables 4 and 5. 
RESULTS 
Only 7.6% of tested individual were children ≤ 15 years old,  most of them were adults in age groups 16-25 
years (28.1%), 26-35 years (27.6%), 36-45years (12.4%) and  ≤46years (24.3%) (table 1). Total end treatment 
rate was 5.94% of the total cases (11/185).  2.7% of total patients show primary infection T.B (low) with 
low contagious, 24.3% show severe infections T.B with highly contagious, and 30.8% show very severe 
infections T.B with highly contagious (table 2). MTB gene was positive for all cases which indicate more 
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sensitive than sputum examination; 3.2% of total patients show RIF's genes positive, while 96.8% of total 
were sensitive to rifampicin (table 3). Higher rate of RIF with male (5.4%) with associated OR equal to 3.1 
times, while RIF rate was 1.8% in female patients.  There was higher rate of RIF with age group 36-45 
years and >15 years in which the rates of RIF gene were 8.7% and 7.1% respectively (table 4). There was 
significant rate of RIF gene with after food drug taken  equal to 13.3%, with OR equal to 6.4 times, and 
with DOTs program equal to 10%, with OR equal to 6.4 times. In addition, there was significant rate of 
RIF's gene with one dose regimen (11.8%), with OR equal to 5.5 times (table 4, 5) 
 
DISCUSSION 
There have been some good achievements over the past decade in tuberculosis control in the countries of 
the WHO Eastern Mediterranean Region including Yemen. These countries have addressed the challenge 
of tuberculosis through implementation of the directly observed treatment, short‐course (DOTS) strategy, 
with the case detection rate reaching 60% for new smear‐positive cases, and an 86% treatment success rate. 
However, multidrug‐resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis 
(XDR‐TB) pose a threat to global and regional public health security and to efforts to reduce the global and 
regional burden of tuberculosis. The Beijing Call for Action on Tuberculosis Control and Patient Care and 
the World Health Assembly resolution WHA62.15 (2009) on prevention and control of multidrug‐resistant 
tuberculosis. Extensively drug‐resistant tuberculosis15 recognizes the challenges posed by multidrug and 
extensively drug‐resistant tuberculosis (M/XDR‐TB) and call for urgent action to address the situation. The 
exact burden of multidrug resistance is not known in the Region since drug resistance surveys have been 
conducted in only eight countries of the Region excluding Yemen. 
   MDR-TB is defined as resistance to both ionized (INH) and rifampicin (RIF), with or without resistance 
to other anti-tuberculosis drugs 
16
. Unlike most other bacteria, resistance in Mycobacterium tuberculosis 
(MTB) develops primarily through mutations in chromosomal genes. These mutations develop 
spontaneously and are sustained in the bacterial population mainly through selective pressure with 
inappropriate treatment 
17,18
. The exact burden of multidrug resistance in Yemen is not known, due to the 
limited number of national drug resistance surveys and surveillance, so that our study was one of 
uncommon study in Yemen and the RFR rate in our study was 3.2% (table 2). This rate (3.2%) was slightly 
higher than 2% of the mean world rates that reported by WHO in the fourth WHO global report on drug 
resistance, Anti‐tuberculosis drug resistance in the world 15. Furthermore, our MDR‐TB rate (3.2%) is 
higher than that reported from Lebanon, Morocco and Oman in which the rates were from 0.5% in Lebanon 
and Morocco to 1.3% in Oman
19
. Additionally, our result was similar to that reported from Yemen 
previously in which the rate was 2.9%, but lower than that from Jordan (5.4%) among new cases of TB 
reported
19
. 
   The resistance to RIF in our study is largely attributed to nucleotide substitutions in an 81-bp core region 
of the rpoB gene as confirmed by Telents 
17,18
 and Pietzka et al. 
20
. In contrast, resistance to INH occurs by 
mutations in several genes, in particular inhA and katG, and to a lesser extent in ahpC,  oxyR,  kasA,  furA  
and ndh 
18,21
. RIF's resistance in our study (3.2%) is regarded as a proxy for MDR-TB as a large proportion 
of RIF resistant strains have INH resistance as described by Caws et al.
22
, Ramaswamg and Mussen 
23
, 
Rieder et al.
24
, Aziz 
25
, Sau et al. 
26
. What's more, theoretically, if RIF's resistance and MDR-TB were 
perfectly correlated, then detection of MDR-TB in Yemen would be sufficient with a single rapid test that 
detects RIF's resistance.  As well, similarly, other parts of the world have also reported that RFR is not 
uncommon. Sanders et al. 
27
 reported that levels of drug resistance in Bujumbura are higher than average 
for Africa and most worrying was the appearance of MDR-TB and RFR in new cases.  Traore et al 
28
 
studied a large number of MTB complex clinical isolates from diverse countries to detect RFR. He reported 
a median of 4.6% RFR with the highest prevalence in Western Europe. Pablos-Mendez et al  
29
 performed 
anti-TB drug resistance surveillance (WHO) in 19 different countries and reported RFR in all. A median of 
1.5% was noted, with the highest rate of 6.9% being reported from both Thailand and Dominican Republic. 
In comparison to the above studies, we report a similar range of RFR. 
   In the current study, males were more likely to have RFR than females. This result is similar to that 
reported from Africa in which males have shown higher prevalence rates of RIF than females 
19
. However, 
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to the best of our knowledge, gender as a specific risk factor for RIF has not previously been documented in 
Yemen by others 
30
. 
Although using age as risk factor is RIF, in the current study RIF was more likely to occur in the 36–45 
year age group. It is well recognized that TB is more common in this age group and that RIF is more 
common in 3
rd
 and 4
th
 decades of life of patients as previously highlighted 
31-33
. Our findings however are in 
contrast to Mukinda et al who reported RIF higher in >45 year age group 
34
. In spite of that the countries in 
the Region including Yemen have been able to make a remarkable improvement in addressing the 
challenge of tuberculosis control through implementation of DOTS during the past decade in public health 
facilities; including primary health care centers with the treatment success rate for 2008 was 87%. In our 
study there was significant association between RF resistant positive cases and positive DOTS treatment in 
which the associated OR was 6.4 times, with CI=1.1-38 and PV=0.02 (table 5). This negative effect for 
DOTS it can be explained by that resistance is a reflection of the mismanagement of tuberculosis cases. 
This mismanagement includes wrong diagnosis and delay of diagnosis, wrong or interrupted treatment, and 
the misuse of tuberculosis medicines, both first‐line and second‐line, such as through poor adherence to 
standardized treatment by private care providers, unregulated sale of anti-tuberculosis medicines and 
utilization of tuberculosis medicines of unknown quality. In addition, the difficulty of patients to reach 
centers for treatment due to the war situation in Yemen. 
CONCLUSION 
Significant number of our patients ended first line treatment due no response, most of them in the first 2 
months of starting treatment. MTB gene was positive for all TB cases which indicate high sensitive rate 
than sputum examination. Significant rate of RIF's genes positive was recorded in our study. There was a 
significant high rate of RIF's gene with previous TB infection. Great risk of develop  RIF gene with DOTs 
program of treatment. The emergence of RF-resistant TB strains in Yemen would make the treatment of TB 
infections more difficult and increase the complications of tuberculosis. As accurate susceptibility data are 
crucial for appropriate therapy decisions, we recommend that microbiology laboratories screen for RF  in 
clinical  isolates before starting treatment. Currently, no single Yemen surveillance study can provide 
estimates of the burden of all factors lead to wide spread of TB drug resistant across acute care TB patient 
populations. 
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Table 1: The age and sex distribution of  T.B patient included in Rifampicin mono-resistance study, at the 
National Tuberculosis Control Programme  in Sana'a city, Yemen.(n=185). 
Age group 
Male (n=74) Female (n=111) Total(185) 
No. % No. % No. % 
≤ 15 year 2 2.7 12 10.8 14 7.6 
16-25 year 19 25.7 33 29.7 52 28.1 
26-35 year 18 24.3 33 29.7 51 27.6 
36-45 year 10 13.5 13 11.7 23 12.4 
≤ 46 year 25 33.8 20 18 45 24.3 
Total 74 40 111 60 185 100 
Mean age 38.6yrs 31.1 34.15 yrs 
S.D 17.9 yrs 14.8 16.5 yrs 
Medial 35 yrs 30yrs 30 yrs 
Mode 20 yrs 30 yrs 30 yrs 
Min 1 yrs 1 yrs 1 yrs 
Max 75 yrs 70 yrs 75 yrs 
 
 
Table 2: The laboratory result of sputum specimens for AFB, MTB gene and RIF's gene for T.B. patients 
under treatment. 
Tests Number Percentage Interpretations 
AFB  
a) 1-9 BPF 5 2.7 primary infection T.B(low) and low contagious 
b) +1  BPF 95 24.3 Moderate infection T.B and low contagious  
c) +2  BPF 57 30.8 Severe infections T.B and Highly contagious 
d) +3  BPF 49 26.5 
Very severe infections T.B 
and Highly contagious 
Negative 24 15.7 
The difficulty of coughing and removing 
sputum is a recent infection with few AFB. 
 
MTB gene  
Positive 185 100 More sensitive than sputum examination 
Negative 0 0 Good diagnosis of suspicion 
RIF genes: 
RR (Resistant) 
6 3.2 
Random use of treatment or treatment or use of 
rifampicin therapy for non-TB disease 
SR (Sensitive) 179 96.8 
Resistant therapy may be a first-line treatment 
other than rifampicin, e.g. Isonazoid 
AFB= Acid fast bacilli,  BPF=Bacilli per field 
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Table 3: The frequency of different period of stop first line treatment due no response (failure) of T.B 
patients, attending NTCP in Sana'a city. 
Period of stop previous  T.B 
treatment (failure) 
Number % 
Interpretations 
- All that patient had previous T.B and 
stopped taking  treatment. 
- The shorter the treatment period, the 
greater the resistance. 
2  Months 5 2.7 
4  Months 0 0 
6 Months 3 1.62 
9 Months 3 1.62 
Total stop (failure) 11 5.94  
 
 
 
 
Table 4: The association of resistant RIF's gene with age and sex of T.B patient under studied. 
Characters 
RIF gene  positive 
(n=6) OR CI X
2
 P 
No. % 
Sex:  
1) Male 
(n=74) 
 
4 
 
5.4 
 
3.1 
 
0.6-17.5 
 
1.8 
 
0.17 
2) Female 
(n=111) 
 
2 
 
1.8 
 
0.32 
 
0.05-1.7 
 
1.8 
 
0.17 
Age groups:  
Less than 15yrs (n=14) 
 
1 
 
7.1 
 
2.6 
 
0.3-23 
 
0.7 
 
0.39 
16-25yrs (n=52) 
 
2 
 
3.8 
 
1.3 
0.2-7.2 
 
0.08 
 
0.77 
26-35yrs (n=51) 
 
1 
 
2 
 
0.51 
0.058-4.5 
 
0.36 
 
0.54 
36-45yrs (n=23) 
 
2 
 
8.7 
 
3.8 
0.64-21.8 
 
2.5 
 
0.11 
≤46years (n=45) 0 0 undefined 1.99 0.15 
Total n=185 6 3.2     
 
OR= Odds ratio, CI=95% confidence interval, X
2
=Chi square, P=probability value 
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Table 5: The associations of Rifampicin Resistance with positive case in the house hold (contacts), time of 
drugs taken and DOTs. 
 
Rifampicin 
Resistance +ve OR CI X
2
 P 
No. % 
House-hold case (contacts):  
1) Yes   (n=29) 0 0 0.0 0.0-4.6 0.25 0.61 
2) No    (n= 155) 6 3.9 0.0 0.22-1 1.2 0.27 
Time and drugs:  
3) Before eat  (n=2) 0 0 0 0-170 0.062 0.79 
4) After food (n=15) 2 13.3 6.4 1.1-38 5.2 0.02 
DOTs:  
5) Yes (n=15) 2 100 6.4 1.1-38 5.2 0.02 
6) No (n=2) 0 0 0.0 0.2-10 5.0 0.02 
Type of dose:  
7) One dose (n=17) 2 11.8 5.5 1-32.3 4.3 0.03 
Two doses (n=0) 0 0 Undefined 
Three doses(n= 1) 0 0 Undefined 
  
OR= Odds ratio, CI=95% confidence interval, X
2
=Chi square, P=probability value 
 
  
 
